The EV-HIV Assay, a Point-of-Care Lateral Flow Immunoassay to Accurately Identify HIV Infection from Blood-Based Extracellular Vesicles

Intuitive Biosciences, Inc., Madison WI

Investigators

Abstract

Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a blood-based, lateral flow HIV diagnostic test that can be employed as point-of-care and as well as for self-testing to differentiate between HIV infection from (VISP).